372 related articles for article (PubMed ID: 33607246)
1. Targeting the tumour microenvironment in platinum-resistant ovarian cancer.
Cummings M; Freer C; Orsi NM
Semin Cancer Biol; 2021 Dec; 77():3-28. PubMed ID: 33607246
[TBL] [Abstract][Full Text] [Related]
2. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
Ghoneum A; Almousa S; Warren B; Abdulfattah AY; Shu J; Abouelfadl H; Gonzalez D; Livingston C; Said N
Semin Cancer Biol; 2021 Dec; 77():83-98. PubMed ID: 33476723
[TBL] [Abstract][Full Text] [Related]
3. The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance.
Motohara T; Yoshida GJ; Katabuchi H
Semin Cancer Biol; 2021 Dec; 77():182-193. PubMed ID: 33812986
[TBL] [Abstract][Full Text] [Related]
4. Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.
Zou X; Zhao Y; Liang X; Wang H; Zhu Y; Shao Q
Front Immunol; 2021; 12():641937. PubMed ID: 33868274
[TBL] [Abstract][Full Text] [Related]
5. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
[TBL] [Abstract][Full Text] [Related]
6. New approaches for targeting platinum-resistant ovarian cancer.
McMullen M; Madariaga A; Lheureux S
Semin Cancer Biol; 2021 Dec; 77():167-181. PubMed ID: 32871277
[TBL] [Abstract][Full Text] [Related]
7. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
8. Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance.
Zhang DX; Vu LT; Ismail NN; Le MTN; Grimson A
Semin Cancer Biol; 2021 Sep; 74():24-44. PubMed ID: 33545339
[TBL] [Abstract][Full Text] [Related]
9. Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy.
Bose S; Saha P; Chatterjee B; Srivastava AK
Semin Cancer Biol; 2022 Nov; 86(Pt 2):568-579. PubMed ID: 35378273
[TBL] [Abstract][Full Text] [Related]
10. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission.
Tyagi K; Mandal S; Roy A
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188563. PubMed ID: 33971276
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
[TBL] [Abstract][Full Text] [Related]
12. TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.
Sonego M; Poletto E; Pivetta E; Nicoloso MS; Pellicani R; Vinciguerra GLR; Citron F; Sorio R; Mongiat M; Baldassarre G
Cells; 2019 Dec; 9(1):. PubMed ID: 31861382
[TBL] [Abstract][Full Text] [Related]
13. Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.
Kim S; Lee M; Dhanasekaran DN; Song YS
BMC Cancer; 2018 Dec; 18(1):1232. PubMed ID: 30526541
[TBL] [Abstract][Full Text] [Related]
14. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
15. Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Atallah GA; Kampan NC; Chew KT; Mohd Mokhtar N; Md Zin RR; Shafiee MNB; Abd Aziz NHB
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768291
[TBL] [Abstract][Full Text] [Related]
16. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract][Full Text] [Related]
17. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.
Pereira M; Matuszewska K; Jamieson C; Petrik J
Front Endocrinol (Lausanne); 2021; 12():772349. PubMed ID: 34867818
[TBL] [Abstract][Full Text] [Related]
18. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
Benard E; Casey NP; Inderberg EM; Wälchli S
Scand J Immunol; 2020 Oct; 92(4):e12917. PubMed ID: 32557659
[TBL] [Abstract][Full Text] [Related]
19. Stem Cells in Tumour Microenvironment Aid in Prolonged Survival Rate of Cancer Cells and Developed Drug Resistance: Major Challenge in Osteosarcoma Treatment.
Birru B; Durthi CP; Kacham S; Pola M; Rajulapati SB; Parcha SR; Kamal MA
Curr Drug Metab; 2020; 21(1):44-52. PubMed ID: 32056519
[TBL] [Abstract][Full Text] [Related]
20. Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.
Wilczyński JR; Wilczyński M; Paradowska E
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
